We are live on ! Find out more

NEUP

Neuphoria Therapeutics

NEUP

Market cap $19.3M

3.56 USD

-0.01

0.28%

At close Updated Sep 30, 4:00 PM EDT

1 day

-0.28%

5 days

-3%

1 month

-5.32%

3 months

-18.54%

6 months

-9.64%

Year to date

-6.81%

1 year

-69.8%

5 years

-97.99%

10 years

-97.99%

About: Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.

Employees: 1

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc. Upon closing of the proposed transaction, Neuphoria shareholders will own 14.5% of the combined company.Halper Sadeh encourages Neuphoria shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or zhalper@halp.

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

NEW YORK, July 24, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Neuphoria Therapeutics, Inc. (NASDAQ: NEUP ) related to its merger with Scancell Holdings plc.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

OXFORD, United Kingdom and BURLINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) (“Scancell”) and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria”) today announce an all-share merger in which Scancell will acquire Neuphoria. Upon completion of the Transaction, the combined company plans to operate under the name Scancell and will apply to trade on Nasdaq under the symbol “SCLT”.

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to an announcement made by London-listed biotechnology company Scancell Holdings plc (“Scancell”).

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the WHITE proxy card FOR BOTH of the Company's director nominees – Peter Miles Davies and David Wilson.

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria's Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP's (“Lynx1”), revised indication of interest to acquire the Company.

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP (“Lynx1”) full of deception and distraction to deflect attention from its own limitations and its handpicked nominees' shortcomings.

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued a letter to its stockholders regarding Neuphoria's 2025 Annual Meeting of Stockholders (“2025 Annual Meeting”), which is scheduled to be held on December 12, 2025.

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

See News Rankings

Price charts implemented using Lightweight Charts™